Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$IONS Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.69 down -188.46% YoY
• Reported revenue of $268M down -40.71% YoY
• Ionis Pharmaceuticals remains on track to achieve its 2026 financial guidance, including full-year product sales targets for TRYNGOLZA and DAWNZERA, while maintaining its goal of cashflow breakeven in 2028.